NASDAQ:ETNB 89BIO Q2 2024 Earnings Report $10.14 +0.04 (+0.40%) Closing price 07/3/2025 02:41 PM EasternExtended Trading$10.14 -0.01 (-0.05%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast 89BIO EPS ResultsActual EPS-$0.48Consensus EPS -$0.56Beat/MissBeat by +$0.08One Year Ago EPS-$0.5289BIO Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/A89BIO Announcement DetailsQuarterQ2 2024Date8/5/2024TimeAfter Market ClosesConference Call DateMonday, August 5, 2024Conference Call Time4:00PM ETUpcoming Earnings89BIO's Q2 2025 earnings is scheduled for Monday, August 4, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) 89BIO Earnings Headlines89BIO (NASDAQ:ETNB) Receives $26.43 Consensus PT from BrokeragesJune 30, 2025 | americanbankingnews.com89BIO (NASDAQ:ETNB) Given "Sell (D-)" Rating at Weiss RatingsJune 28, 2025 | americanbankingnews.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.July 5 at 2:00 AM | Brownstone Research (Ad)89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.com89bio to Participate in Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | globenewswire.com89bio (ETNB) Receives a Buy from Bank of America SecuritiesMay 29, 2025 | theglobeandmail.comSee More 89BIO Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 89BIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89BIO and other key companies, straight to your email. Email Address About 89BIO89BIO (NASDAQ:ETNB), Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for metabolic and fibrotic diseases. The company’s lead candidate, pegozafermin, is a long-acting, pegylated analog of fibroblast growth factor 21 (FGF21) designed to address underlying drivers of metabolic dysfunction, including liver fat accumulation, lipid abnormalities and inflammation. In addition to pegozafermin, 89bio is advancing a pipeline of next-generation FGF21-based molecules and receptor agonists aimed at treating a range of conditions linked to metabolic health. Since its founding in 2018, 89bio has initiated multiple Phase 2 clinical trials evaluating pegozafermin in nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia and other disorders characterized by insulin resistance and liver fibrosis. Early-stage studies have demonstrated improvements in key biomarkers such as liver fat content, triglyceride levels and markers of liver injury. The company’s strategic focus on a biology-driven approach supports potential expansion into complementary indications, including cardiovascular disease and chronic kidney disease in patients with metabolic syndrome. Based in South San Francisco, California, 89bio serves patients worldwide through its clinical partnerships and global trial network. The company was founded by a team of biotechnology veterans and academic scientists to translate foundational insights in hormone biology into practical therapies. Under the leadership of CEO and President Farhad Gen, Ph.D., 89bio has assembled a management team with deep experience in drug development, regulatory affairs and commercial strategy. The company is backed by leading life science investors and collaborates with research institutions to accelerate its pipeline toward regulatory milestones and potential commercialization.Written by Jeffrey Neal JohnsonView 89BIO ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
